What the research shows
A randomized trial assigned 412 adults with HIV and excess abdominal fat to tesamorelin or placebo. After 26 weeks, CT-measured visceral fat fell by 15.2% in the tesamorelin group and rose by 5.0% in the placebo group. This endpoint concerns fat inside the abdomen. Randomized trial of visceral fat in HIV.
The Egrifta WR label distinguishes WR and SV by formulation, strength and handling. It explicitly states that they cannot be substituted for one another. FDA prescribing information for Egrifta WR.
Documented formats
Egrifta WR is supplied as freeze-dried powder in a vial. Egrifta SV is a distinct vial presentation with separate labeling.
Testing and purity
Match the full WR or SV product name, vial strength and lot. Recording only the active ingredient loses a distinction that the approved label considers important.
How to read a batch reportQuestions about Tesamorelin
Did the trial measure total weight loss?
Its primary outcome was change in visceral fat area on a CT image. A change in that area cannot be read as a percentage change in body weight.
Does the label describe a tesamorelin–ipamorelin mixture?
The labeled active ingredient is tesamorelin. A mixture containing another active peptide would be a different product.